ArticleBMC biotechnology2012
M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses.
Article in BMC biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 63 citations in OpenAlex.
- Proteomic Profiling Identifies CLDN3 as a Tumor-Selective Therapeutic Target in Small Cell Lung Cancer.bioRxiv : the preprint server for biology · 2026Article
- Leishmaniasis: pathogenesis, host immunity, and the evolving landscape of immunotherapy and immunochemotherapy.Frontiers in microbiology · 2026Review
- Structure-guided design of a novel, stable, and soluble Cecropin A variant for antimicrobial therapeutic applications.Scientific reports · 2025Article
- In silico design and evaluation of a multiepitope vaccine against Bordetella pertussis: structural, immunological, and biological properties.Genomics & informatics · 2025Article
- Structural and biophysical insights into targeting of claudin-4 by a synthetic antibody fragment.Communications biology · 2024Article
- Discrimination of distinct chicken M cell subsets based on CSF1R expression.Scientific reports · 2024Article
- Recombinant L. lactis vaccine LL-plSAM-WAE targeting four virulence factors provides mucosal immunity against H. pylori infection.Microbial cell factories · 2024Article
- Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake.Frontiers in immunology · 2024Review
- Cracking the intestinal lymphatic system window utilizing oral delivery vehicles for precise therapy.Journal of nanobiotechnology · 2023Review
- Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.Scientific reports · 2023Article
- Dietary fiber alters immunity and intestinal barrier function of different breeds of growing pigs.Frontiers in immunology · 2023Article
- Oral drug delivery for immunoengineering.Bioengineering & translational medicine · 2022Review
- Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome.Advanced drug delivery reviews · 2021Review
- Formulation technologies for oral vaccines.Clinical and experimental immunology · 2019Review
- M Cells: Intelligent Engineering of Mucosal Immune Surveillance.Frontiers in immunology · 2019Review
- Oral Vaccine Delivery for Intestinal Immunity-Biological Basis, Barriers, Delivery System, and M Cell Targeting.Polymers · 2018Review
- Development of Adjuvant-Free Bivalent Food Poisoning Vaccine by Augmenting the Antigenicity ofFrontiers in immunology · 2018Article
- Current state and challenges in developing oral vaccines.Advanced drug delivery reviews · 2017Review
- The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants.Clinical and experimental vaccine research · 2017Review
- Mechanisms of mycobacterial transmission: how does Mycobacterium tuberculosis enter and escape from the human host.Future microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMucosal immune surveillance is thought to be largely achieved through uptake by specialized epithelial M cells. We recently identified Claudin 4 as an M cell target receptor and developed a Claudin 4 targeting peptide (CPE) that can mediate uptake of nanoparticles through Nasal Associated Lymphoid Tissue (NALT) M cells.
methodsRecombinant influenza hemagglutinin (HA) and a version with the CPE peptide at the C-terminal end was used to immunize mice by the intranasal route along with a single dose of cholera toxin as an adjuvant. Serum and mucosal IgG and IgA responses were tested for reactivity to HA.
resultsWe found that the recombinant HA was immunogenic on intranasal administration, and inclusion of the CPE targeting peptide induced higher mucosal IgA responses. This mucosal administration also induced systemic serum IgG responses with Th2 skewing, but targeting did not enhance IgG responses, suggesting that the IgG response to mucosal immunization is independent of the effects of CPE M cell targeting.
conclusionsM cell targeting mediated by a Claudin 4-specific targeting peptide can enhance mucosal IgA responses above the response to non-targeted mucosal antigen. Since Claudin 4 has also been found to be regulated in human Peyer's patch M cells, the CPE targeting peptide could be a reasonable platform delivery technology for mucosal vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.